Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AB 1003 - Asklepios BioPharmaceutical

Next Previous
X
Search
Drug Profile

AB 1003 - Asklepios BioPharmaceutical

Alternative Names: AB-1003 - Asklepios BioPharmaceutical; LION-101

Latest Information Update: 02 Mar 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Asklepios BioPharmaceutical
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limb girdle muscular dystrophies
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Limb girdle muscular dystrophies

Most Recent Events

  • 27 Feb 2023 Phase-I/II clinical trials in Limb girdle muscular dystrophies (In adults, In the elderly) in USA (IV) (NCT05230459)
  • 27 Feb 2023 AB 1003 - Asklepios BioPharmaceutical receives Orphan Drug status for Limb girdle muscular dystrophies in European Union
  • 28 Jun 2021 AB 1003 receives Fast Track designation for Limb girdle muscular dystrophies [IV] in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top